Q2 2025 Krystal Biotech Inc Earnings Call Transcript
Key Points
- Krystal Biotech Inc (KRYS) reported a profitable quarter with an EPS of $1.29 per share, marking two years of consistently positive earnings.
- The company achieved $96 million in net VYJUVEK revenue for Q2 2025, contributing to a total of over $525 million since launch.
- Krystal Biotech Inc (KRYS) has secured over 575 reimbursement approvals for VYJUVEK in the US, indicating strong market penetration.
- The company is expanding its global footprint with upcoming launches in Europe and Japan, which are expected to drive significant growth.
- Krystal Biotech Inc (KRYS) maintains a strong balance sheet with over $820 million in cash and investments, supporting future growth initiatives.
- The company anticipates a decline in Q3 2025 revenues due to seasonal pauses and unpredictability in patient treatment patterns.
- Compliance rates for VYJUVEK are expected to decrease as severe patients achieve durable wound closure, impacting future revenue consistency.
- The sales force expansion is still underway, and the full impact of new hires will not be realized until future quarters.
- There is inherent unpredictability in quarter-to-quarter revenue due to the variable nature of patient restarts and treatment pauses.
- The European launch is subject to the continuity of the Acces Precoce early access program in France, which poses a potential risk.
Thank you for standing by, and welcome to the Krystal Biotech Q2 2025 earnings call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development. Please begin.
Good morning, and thank you all for joining today's call. Earlier today, we released our financial results for the second quarter of 2025. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today.
Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Laurent Goux, Senior Vice President and General Manager for Europe, and Kate Romano, Chief Accounting Officer.
This conference call will and our responses to questions may contain forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
